European urology最新文献

{"title":"Re: Sobia Khan, Nathan Papa, Andrew Kneebone, et al. Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium [68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Urol 2026;89:512–20","authors":"Elif Hindié,Aurélien Callaud,Clément Morgat","doi":"10.1016/j.eururo.2026.08.028","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.08.028","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"32 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accumulating Evidence Supports NECTIN4 as a Predictive Biomarker for Enfortumab Vedotin: The Compartment Still Matters","authors":"Niklas Klümper,Jonathan E. Rosenberg,David H. Aggen,Markus Eckstein","doi":"10.1016/j.eururo.2026.09.008","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.09.008","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"13 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Comes After Matters: The Importance of Postprogression Care in Patients with Metastatic Hormone-sensitive Prostate Cancer","authors":"Ashkan Mortezavi, Tom van der Hulle, Roderick van den Bergh","doi":"10.1016/j.eururo.2026.07.001","DOIUrl":"10.1016/j.eururo.2026.07.001","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages 311-314"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148581782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-invasive Bladder Cancer. J Clin Oncol. In press. http://dx.doi.org/10.1200/JCO-25-02093","authors":"Jianguang Miao, Xinyu Yi","doi":"10.1016/j.eururo.2026.06.018","DOIUrl":"10.1016/j.eururo.2026.06.018","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages e92-e93"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Alexander Light, Max Peters, Manit Arya, et al’s Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer. JAMA Oncol 2026;12:364–73.","authors":"Marcio Covas Moschovas, Ugo Falagario, Francesco Pellegrino, Peter Wiklund, Vipul Patel","doi":"10.1016/j.eururo.2026.05.031","DOIUrl":"10.1016/j.eururo.2026.05.031","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages e83-e84"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148229679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications","authors":"Can Aydogdu,&nbsp;Laura Bukavina,&nbsp;Liang Cheng,&nbsp;Hikmat A. Al-Ahmadie,&nbsp;Omar Alhalabi,&nbsp;Jason R. Brown,&nbsp;Antonio Lopez-Beltran,&nbsp;Petros Grivas,&nbsp;Clara Hwang,&nbsp;G. Daniel Grass,&nbsp;Ashish M. Kamat,&nbsp;Jonathan Chatzkel,&nbsp;Omar Mian,&nbsp;Andrea Necchi,&nbsp;Jeff Ross,&nbsp;Andrea B. Apolo,&nbsp;Philippe E. Spiess,&nbsp;Roger Li","doi":"10.1016/j.eururo.2026.05.030","DOIUrl":"10.1016/j.eururo.2026.05.030","url":null,"abstract":"<div><h3>Background and objective</h3><div>Histological subtypes and divergent differentiation are common in bladder cancer. Each subtype has distinct biology and clinical features. We aim to summarize pathology, molecular features, and outcomes of the most common bladder cancer subtypes to guide management.</div></div><div><h3>Methods</h3><div>We performed a narrative review of cohort studies, clinical trials, and population-based analyses assessing morphology, immunophenotype, genomic alterations, and outcomes following various localized and systemic therapies in patients with bladder cancer subtypes.</div></div><div><h3>Key findings and limitations</h3><div>Histological subtypes are often understaged on transurethral resection of bladder tumor and commonly demonstrate lymph node metastasis, supporting early radical cystectomy (RC) even for certain clinically non–muscle-invasive bladder cancers. Small cell urothelial carcinoma (UC) consistently benefits from platinum/etoposide-based chemotherapy regimens, whereas predominant squamous, plasmacytoid, sarcomatoid, and micropapillary tumors demonstrate variable response rates to systemic therapies used in conventional UC. Trimodality therapy may approximate RC in locoregional control for small cell UC and appears inferior in cases with predominant squamous and adenocarcinoma. Genomic profiling highlights actionable alterations, albeit with unclear clinical implications. Immune checkpoint blockade and antibody-drug conjugates have been used sparingly against subtype bladder cancers and have anecdotally demonstrated activity across several subtypes.</div></div><div><h3>Conclusions and clinical implications</h3><div>Histological subtypes and divergent differentiation of UC represent high-risk yet biologically distinct disease phenotypes that may not conform to the current “one-size-fits-all” treatment paradigm. More in-depth clinical and translational analyses with robust, adequately powered cohorts are required to further understand the clinical behavior of each unique bladder cancer subtype and to customize the optimal therapeutic strategies.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages 377-388"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148341547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics","authors":"Stefano Fanti,&nbsp;Fabio Turco,&nbsp;Bertrand Tombal,&nbsp;Jochen Walz,&nbsp;Michael S. Hofman,&nbsp;Boris Hadaschik,&nbsp;Louise Emmett,&nbsp;Derya Tilki,&nbsp;Giovanna Pecoraro,&nbsp;Giuseppe Salfi,&nbsp;Gerhardt Attard,&nbsp;Himisha Beltran,&nbsp;Anders Bjartell,&nbsp;Alberto Briganti,&nbsp;Irene A. Burger,&nbsp;Elena Castro,&nbsp;Juliano J. Cerci,&nbsp;Arturo Chiti,&nbsp;Matthew Cooperberg,&nbsp;Karim Fizazi,&nbsp;Ken Herrmann","doi":"10.1016/j.eururo.2026.06.009","DOIUrl":"10.1016/j.eururo.2026.06.009","url":null,"abstract":"<div><h3>Background and objective:</h3><div>For over a decade the Advanced Prostate Cancer Consensus Conference (APCCC) covers a variety of topics that greatly impact daily practice. In 2025, a dedicated event was organised to discuss key questions in clinical management of patients with prostate cancer (PC) related to diagnostic tools (APCCC Diagnostics). Here we present the voting results of the APCCC Diagnostics questions.</div></div><div><h3>Methods:</h3><div>APCCC Diagnostics 2025 is a pilot project. The scientific committee for APCCC Diagnostics 2025 developed 88 multiple-choice consensus questions on six different topics. Prior to the conference, the panel members (‘‘panellists’’) voted on these questions via a web-based survey. Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement.</div></div><div><h3>Key findings and limitations:</h3><div>Consensus was only reached on 17 of 88 questions (19%), of which six (7%) received a strong consensus. Specifically, consensus was reached for two of 17 questions (14%) in “how to diagnose PC”; seven of 16 (44%) in “how to stage PC”; three of 14 (21%) in “Biochemical Recurrence Scenario”; two of 11 (18%) in “metastatic disease: what to do?”; zero of 18 (0%) in “monitoring metastatic PC”; and three of 12 (25%) in “radioligand therapy and imaging.”</div></div><div><h3>Conclusions and clinical implications:</h3><div>The voting results and their discussion may assist physicians in navigating controversial areas of clinical management related to diagnosis, staging, and restaging in the different clinical settings for PC, particularly where high-level evidence is scarce or conflicting. The findings can also help funders and policymakers in prioritising areas for future research.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"90 4","pages":"Pages 347-376"},"PeriodicalIF":29.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148383397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Perioperative Apalutamide in High-risk Localized Prostate Cancer","authors":"Gregory M. Hemenway,Daniel M. Geynisman","doi":"10.1016/j.eururo.2026.09.006","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.09.006","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"30 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149092031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Matthew Lee, Michael Lesgart, Connor McPartland, Randall Lee, Daniel D. Eun. Robotic Transvesical Bladder Neck Reconstruction: A Novel Approach to Managing Vesicourethral Anastomotic Stenosis. Eur Urol 2025;88:519–24","authors":"Marco Bandini,Francesco Montorsi","doi":"10.1016/j.eururo.2026.01.034","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.01.034","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"294 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: A Randomized Controlled Trial Comparing En-bloc Versus Lobe-by-lobe HoLEP: Surgical Efficiency and Early Continence Outcomes","authors":"Theodoros Spinos,Panagiotis Kallidonis","doi":"10.1016/j.eururo.2026.09.013","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.09.013","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"6 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149088860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}